Determination of serum imatinib and its' metabolite in patients chronic myeloid leukemia


Onmaz D. E., Abusoglu S., Unlu A., BAŞTÜRK A., Dagli M., Bagci M., ...Daha Fazla

Clinica Chimica Acta, cilt.497, ss.120-124, 2019 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 497
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1016/j.cca.2019.07.025
  • Dergi Adı: Clinica Chimica Acta
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.120-124
  • Anahtar Kelimeler: Therapeutic drug monitoring, Imatinib, Tandem mass spectrometry, Validation
  • Sağlık Bilimleri Üniversitesi Adresli: Hayır

Özet

Introduction: Imatinib has favorable pharmacokinetic properties, but primary and secondary resistance mechanisms may cause a decrease in clinical response over time. There is a positive correlation between serum imatinib concentrations and treatment response. Our aim was to develop a method for the measurement of imatinib and its' active metabolite N-desmethyl imatinib. Methods: Serum imatinib and N-desmethyl imatinib levels were determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and validation studies were carried out according to CLSI (The Clinical & Laboratory Standards Institute) protocols. Serum samples were collected from 40 patients with chronic myeloid leukemia (CML) and analyzed with LC-MS/MS and ultra high-performance liquid chromatography (UHPLC) methods. Results: The linearity range and correlation coefficient were 12.2–12,500 ng/mL and 0.9987 for LC-MS/MS method, respectively. Limit of quantitation was determined as 24.4 ng/mL. The retention times of imatinib and N-desmethyl imatinib were 1.66 and 1.60 min, respectively. There was no statistically significant difference between the results of both methods. Discussion: This LC-MS/MS method is cost-effective and has adavantages such as using low serum volumes, requiring simple pretreatment steps (only protein precipitation) and reduced turnaround times for analysis.